Document is current
Any future updates will be listed below
-
Authors
Wan, Xiayun
Eguchi, Akifumi
Qu, Youge
Yang, Yong
Chang, Lijia
Shan, Jiajing
Mori, Chisato
Hashimoto, Kenji https://orcid.org/0000-0002-8892-0439
-
Funding
Funding for this research was provided by:
National Center of Neurology and Psychiatry (1-1)
Japan Society for the Promotion of Science (21H00184, 21H05612)
Japan Science and Technology Corporation (JPMJOP1831)
- License Information
-
More Information
Article History
Received: 17 March 2022
Accepted: 15 May 2022
First Online: 6 June 2022
Declarations
:
: Dr. K. Hashimoto is the inventor of filed patent applications on “The use of <i>R</i>-Ketamine in the treatment of psychiatric diseases”, “(<i>S</i>)-norketamine and salt thereof as pharmaceutical”, “<i>R</i>-Ketamine and derivative thereof as prophylactic or therapeutic agent for neurodegeneration disease or recognition function disorder”, “Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases”, and “<i>R</i>-Ketamine and its derivatives as a preventive or therapeutic agent for a neurodevelopmental disorder” by the Chiba University. Dr. K. Hashimoto has also received speakers’ honoraria, consultant fee, or research support from Abbott, Meiji Seika Pharma, Daiichi-Sankyo, Dainippon-Sumitomo, Taisho, Otsuka, Seikagaku Corporation, Murakami Farm and Perception Neuroscience. Other authors declare no conflict of interest.
